Fatostatin

• Description :

  Fatostatin (125B11), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin decreases the transcription of lipogenic genes in cells. Fatostatin possesses antitumor properties, and lowers hyperglycemia in ob/ob mice[1][2].

• Product Name Alternative :

  125B11

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Fatty Acid Synthase (FASN)

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Fatostatin-A.html

• Purity :

  99.85

• Solubility :

  DMSO : ≥ 27 mg/mL

• Smiles :

  CCCC1=NC=CC(C2=NC(C3=CC=C(C)C=C3)=CS2)=C1

• Molecular Formula :

  C18H18N2S

• Molecular Weight :

  294.41

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Li X et al. Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling. Mol Cancer Ther. 2014 Apr;13 (4) :855-66.|[2]Shao W et al. Fatostatin blocks ER exit of SCAP but inhibits cell growth in a SCAP-independent manner. J Lipid Res. 2016 Aug;57 (8) :1564-73.|[3]Inoue K et al. Fatostatin, an SREBP inhibitor, prevented RANKL-induced bone loss by suppression of osteoclast differentiation. Biochim Biophys Acta. 2015 Nov;1852 (11) :2432-41.|[4]Choi Y, et al. Identification of bioactive molecules by adipogenesis profiling of organic compounds. J Biol Chem. 2003 Feb 28;278 (9) :7320-4.|[5]Kamisuki S, et al. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem Biol. 2009 Aug 28;16 (8) :882-92.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Citation 01 :

  Adv Sci (Weinh) . 2025 Apr 24:e2407671.|Autophagy. 2021 Jul;17 (7) :1592-1613.|Biochim Biophys Acta Mol Cell Biol Lipids. 2025 Jun 6:159642.|Biol Pharm Bull. 2022 Apr 1;45 (4) :438-445.|Br J Nutr. 2024 Feb 28;131 (4) :553-566.|Cancer Cell. 2024 Sep 26:S1535-6108 (24) 00350-7.|Cancer Lett. 2024 Jun 18:217068.|Cancers (Basel) . 2023 Jun 3;15 (11) :3043.|Cell Biosci. 2023 Oct 3;13 (1) :186.|Cell Death Differ. 2021 Jun;28 (6) :2001-2018.|Cell Death Dis. 2021 May 26;12 (6) :544.|Cell Death Dis. 2024 Jun 12;15 (6) :411.|Cell Death Dis. 2025 May 16;16 (1) :391.|Cell Death Discov. 2022 Oct 28;8 (1) :431.|Cell Metab. 2021 Aug 3;33 (8) :1655-1670.e8.|Cell Mol Biol Lett. 2024 Aug 21;29 (1) :112.|Cell Mol Immunol. 2025 Oct 29.|Cell Mol Life Sci. 2024 Jul 6;81 (1) :289.|Cell Mol Life Sci. 2025 Jul 3;82 (1) :270.|Cell Rep. 2022 Nov 29;41 (9) :111738.|Cell Rep. 2025 Feb 19;44 (3) :115339.|Emerg Microbes Infect. 2025 Dec;14 (1) :2470371.|Eur J Pharmacol. 2025 Sep 15:1003:177890.|Exp Eye Res. 2025 Jan 10:110239.|Int Immunopharmacol. 2024 Jul 18:139:112669.|iScience. 2024 Jun 29;27 (8) :110424.|J Cell Mol Med. 2025 Jul;29 (14) :e70710.|J Clin Invest. 2025 Jul 8:e193134.|J Ethnopharmacol. 2024 Jan 30;319 (Pt 1) :117162.|J Ethnopharmacol. 2026 Feb 28:357:120890.|J Exp Clin Cancer Res. 2019 May 29;38 (1) :228. |J Pathol. 2020 Dec;252 (4) :358-370.|JCI Insight. 2024 Jun 18:e180132.|Mol Carcinog. 2023 Jul;62 (7) :963-974.|Mol Med. 2024 Feb 21;30 (1) :28.|Mol Oncol. 2025 Jun;19 (6) :1668-1686.|Nat Commun. 2025 Feb 1;16 (1) :1241.|Nat Commun. 2025 Feb 25;16 (1) :1774.|NPJ Precis Oncol. 2024 Mar 1;8 (1) :58.|Oncol Lett. 2020 Sep;20 (3) :2855-2869.|Oncol Rep. 2018 Apr;39 (4) :1919-1929.|Res Sq. 2024 Nov 18.|Research Square Preprint. 2022 May.|Tissue Cell. 2025 Sep 9:98:103134.|University of Tubingen. 2025.|Free Radic Biol Med. 2025 Aug 19:240:170-182.

• CAS Number :

  [125256-00-0]